Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From 89bio, Inc.
With its GLP-1 analog already a stalwart in type 2 diabetes and weight loss, Novo Nordisk is investigating semaglutide as monotherapy and in combination regimens to treat non-alcoholic steatohepatitis.
At AASLD, 89bio presented subgroup analysis from its successful Phase IIb NASH study indicating that the drug may meaningfully reduce fibrosis even in the sickest patients, those with cirrhosis.
Already prepping Phase III trials of efruxifermin in pre-cirrhotic NASH patients, Akero says it will go ahead with Phase III plans in cirrhotic patients despite missing the fibrosis endpoint in a Phase IIb trial.
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.
- Other Names / Subsidiaries
- 89bio Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.